Summit Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Summit Therapeutics PLC
SMMT Stock  USD 17.04  0.00  0.00%   
Analyzing historical trends in various income statement and balance sheet accounts from Summit Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Summit Therapeutics' valuation are summarized below:
Gross Profit
705 K
Market Capitalization
12.7 B
Enterprise Value Revenue
6.4 K
Earnings Share
(1.25)
Quarterly Revenue Growth
(1.00)
There are currently one hundred twenty fundamental trend indicators for Summit Therapeutics PLC that can be evaluated and compared over time across competition. All traders should double-check Summit Therapeutics' current fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 12.1 B in 2026. Working Capital is likely to gain to about 49.3 M in 2026

Summit Therapeutics Total Revenue

0.0

Check Summit Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Summit Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 20.7 M, Interest Expense of 10.5 M or Selling General Administrative of 73.1 M, as well as many indicators such as Price To Sales Ratio of 1.3 K, Dividend Yield of 0.0 or PTB Ratio of 48.03. Summit financial statements analysis is a perfect complement when working with Summit Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Summit Stock
Check out the analysis of Summit Therapeutics Correlation against competitors.

Summit Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets525.9 M500.9 M171.3 M
Slightly volatile
Total Current Liabilities50.4 M48 M19.4 M
Slightly volatile
Property Plant And Equipment Net8.9 M8.5 M2.6 M
Slightly volatile
Accounts Payable3.4 M5.3 M4 M
Pretty Stable
Cash126.6 M120.6 M65.4 M
Slightly volatile
Non Current Assets Total12.2 M13.6 M11.3 M
Slightly volatile
Cash And Short Term Investments497.9 M474.2 M132.9 M
Slightly volatile
Common Stock Total Equity706.2 K743.4 K3.1 M
Slightly volatile
Common Stock Shares Outstanding867.6 M826.3 M233.8 M
Slightly volatile
Liabilities And Stockholders Equity525.9 M500.9 M171.3 M
Slightly volatile
Non Current Liabilities Total5.6 M5.8 M42.1 M
Pretty Stable
Other Current Assets18.7 M12.5 M23.3 M
Pretty Stable
Other Stockholder Equity1.9 B1.8 B495.5 M
Slightly volatile
Total Liabilities48.7 M53.8 M60.9 M
Slightly volatile
Total Current Assets511.7 M487.3 M159.8 M
Slightly volatile
Intangible Assets7.1 M12 M7.9 M
Slightly volatile
Common Stock4.7 M6.6 M4.7 M
Pretty Stable
Net Receivables608.5 K640.5 K4.3 M
Pretty Stable
Property Plant And Equipment Gross10.3 M9.8 M3.2 M
Slightly volatile
Good Will1.6 M1.7 M2.6 M
Slightly volatile
Property Plant Equipment6.1 M5.8 M2.1 M
Slightly volatile
Other Liabilities1.2 M1.3 M5.7 M
Pretty Stable
Net Invested Capital226.3 M447.1 M134.7 M
Slightly volatile
Net Working Capital461.3 M439.3 M147.8 M
Slightly volatile
Capital Stock8.9 M8.5 M3.3 M
Slightly volatile

Summit Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization20.7 M19.7 M3.9 M
Slightly volatile
Interest Expense10.5 M10 M3.3 M
Slightly volatile
Selling General Administrative73.1 M69.6 M21.6 M
Slightly volatile
Other Operating Expenses273.3 M260.3 M77.8 M
Slightly volatile
Research Development182.1 M173.4 M57.1 M
Slightly volatile
Selling And Marketing Expenses1.4 M2.4 M1.4 M
Slightly volatile
Reconciled Depreciation97.2 K102.3 K917.2 K
Slightly volatile

Summit Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation97.2 K102.3 K778.1 K
Slightly volatile
Capital Expenditures118.8 K125.1 K213.2 K
Pretty Stable
Total Cash From Financing Activities460.3 M438.4 M134.5 M
Slightly volatile
End Period Cash Flow62 M121 M79.3 M
Slightly volatile
Stock Based Compensation61.6 M58.6 M13.2 M
Slightly volatile
Issuance Of Capital Stock577.1 M549.6 M134.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.3 K1.3 K3.9 K
Slightly volatile
Days Sales Outstanding3 K2.9 K1.8 K
Slightly volatile
Invested Capital58.9 M56.1 M58.1 M
Slightly volatile
Average Payables2.3 M3.9 M4 M
Slightly volatile
Stock Based Compensation To Revenue13.2612.634.6334
Slightly volatile
Capex To Depreciation1.561.80.9551
Very volatile
Inventory Turnover94.1 K89.7 K92.8 K
Slightly volatile
Days Of Inventory On Hand0.00310.00332.4914
Slightly volatile
Payables Turnover3.062.912.2385
Slightly volatile
Sales General And Administrative To Revenue35.8334.1216.1596
Slightly volatile
Research And Ddevelopement To Revenue69.7766.4533.9743
Slightly volatile
Capex To Revenue0.811.020.3503
Slightly volatile
Cash Per Share0.460.520.5821
Slightly volatile
Days Payables Outstanding96.4110121.9 K
Slightly volatile
Net Current Asset Value113.8 K128.1 K139.8 K
Slightly volatile
Tangible Asset Value49.4 M47 M48.7 M
Slightly volatile
Intangibles To Total Assets0.00470.00490.1238
Slightly volatile
Current Ratio12.011.688.1798
Very volatile
Receivables Turnover0.130.11521.753
Slightly volatile
Debt To Equity0.01590.01670.336
Slightly volatile
Capex Per Share2.0E-42.0E-40.0039
Slightly volatile
Average Receivables7.3 M7 M4.5 M
Slightly volatile
Revenue Per Share0.00310.00330.095
Pretty Stable
Interest Debt Per Share0.01890.01990.1868
Pretty Stable
Debt To Assets0.01420.01490.0891
Slightly volatile
Graham Number1.031.161.2691
Slightly volatile
Operating Cycle3.8 K3.6 K1.9 K
Slightly volatile
Days Of Payables Outstanding96.4110121.9 K
Slightly volatile
Long Term Debt To Capitalization0.790.512.5713
Slightly volatile
Total Debt To Capitalization0.01560.01640.0956
Slightly volatile
Debt Equity Ratio0.01590.01670.336
Slightly volatile
Quick Ratio11.9611.688.1447
Very volatile
Net Income Per E B T0.770.90.9345
Very volatile
Cash Ratio2.752.895.3262
Slightly volatile
Days Of Inventory Outstanding0.00310.00332.4914
Slightly volatile
Days Of Sales Outstanding3 K2.9 K1.8 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.211.151.0329
Slightly volatile
Fixed Asset Turnover0.150.1622.4285
Slightly volatile
Debt Ratio0.01420.01490.0891
Slightly volatile
Price Sales Ratio1.3 K1.3 K3.9 K
Slightly volatile
Asset Turnover9.0E-40.0010.1323
Slightly volatile

Summit Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap12.1 B11.5 B5.3 B
Slightly volatile
Working Capital49.3 M47 M48.7 M
Slightly volatile

Summit Fundamental Market Drivers

Summit Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Summit Therapeutics Financial Statements

Summit Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Summit Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Summit Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Summit Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue16.3 M17.2 M
Cost Of Revenue17.3 M16.4 M
Stock Based Compensation To Revenue 12.63  13.26 
Sales General And Administrative To Revenue 34.12  35.83 
Research And Ddevelopement To Revenue 66.45  69.77 
Capex To Revenue 1.02  0.81 
Ebit Per Revenue(97.37)(92.50)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Summit Stock Analysis

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY